Rock Springs Capital Management
Latest statistics and disclosures from Rock Springs Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BPMC, UNH, ISRG, NBIX, LLY, and represent 23.58% of Rock Springs Capital Management's stock portfolio.
- Added to shares of these 10 stocks: INSM (+$54M), GPCR (+$26M), JNJ (+$25M), UNH (+$23M), LLY (+$17M), CGEM (+$12M), NUVL (+$9.9M), TVTX (+$8.7M), SWTX (+$7.5M), RARE (+$6.1M).
- Started 8 new stock positions in CATX, ALLK, INSM, APLS, JNJ, KRRO, CGEM, SWTX.
- Reduced shares in these 10 stocks: IMCR (-$66M), Shockwave Med (-$44M), PEN (-$43M), BSX (-$32M), AGIO (-$31M), OLK (-$30M), SGRY (-$29M), IDXX (-$29M), PODD (-$25M), FRPT (-$24M).
- Sold out of its positions in AMLX, CERE, CGON, COLL, IRON, Neurocrine Biosciences Inc Note 2.250 5/1, RPHM, Shockwave Med, SGRY, VKTX. IMTX.
- Rock Springs Capital Management was a net seller of stock by $-388M.
- Rock Springs Capital Management has $3.3B in assets under management (AUM), dropping by -15.65%.
- Central Index Key (CIK): 0001595725
Tip: Access up to 7 years of quarterly data
Positions held by Rock Springs Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv![Download consolidated filings csv](/static/img/csv.png)
![Download consolidated filings xlsx](/static/img/microsoft-excel.png)
Portfolio Holdings for Rock Springs Capital Management
Rock Springs Capital Management holds 110 positions in its portfolio as reported in the June 2024 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Blueprint Medicines (BPMC) | 8.2 | $271M | 2.5M | 107.78 |
|
|
UnitedHealth (UNH) | 4.2 | $140M | +19% | 275k | 509.26 |
|
Intuitive Surgical Com New (ISRG) | 4.0 | $133M | 299k | 444.85 |
|
|
Neurocrine Biosciences (NBIX) | 3.9 | $129M | -10% | 940k | 137.67 |
|
Eli Lilly & Co. (LLY) | 3.3 | $110M | +17% | 122k | 905.38 |
|
Argenx Se Sponsored Adr (ARGX) | 3.0 | $99M | 229k | 430.04 |
|
|
Acadia Healthcare (ACHC) | 2.4 | $80M | 1.2M | 67.54 |
|
|
Ultragenyx Pharmaceutical (RARE) | 2.4 | $79M | +8% | 1.9M | 41.10 |
|
Evolent Health Cl A (EVH) | 2.3 | $78M | +2% | 4.1M | 19.12 |
|
Madrigal Pharmaceuticals (MDGL) | 2.1 | $69M | -14% | 246k | 280.16 |
|
Boston Scientific Corporation (BSX) | 1.9 | $63M | -33% | 818k | 77.01 |
|
Freshpet (FRPT) | 1.9 | $62M | -27% | 480k | 129.39 |
|
Alnylam Pharmaceuticals (ALNY) | 1.8 | $61M | -9% | 250k | 243.00 |
|
Mirum Pharmaceuticals (MIRM) | 1.8 | $61M | -4% | 1.8M | 34.19 |
|
Merus N V (MRUS) | 1.8 | $59M | -12% | 1.0M | 59.17 |
|
IDEXX Laboratories (IDXX) | 1.8 | $58M | -33% | 120k | 487.20 |
|
Agilon Health (AGL) | 1.8 | $58M | 8.9M | 6.54 |
|
|
Dex (DXCM) | 1.7 | $57M | -16% | 500k | 113.38 |
|
Humana (HUM) | 1.7 | $55M | 147k | 373.65 |
|
|
Insmed Com Par $.01 (INSM) | 1.6 | $54M | NEW | 808k | 67.00 |
|
Rhythm Pharmaceuticals (RYTM) | 1.6 | $53M | -15% | 1.3M | 41.06 |
|
Celldex Therapeutics Com New (CLDX) | 1.6 | $52M | 1.4M | 37.01 |
|
|
Phreesia (PHR) | 1.5 | $51M | +2% | 2.4M | 21.20 |
|
Edwards Lifesciences (EW) | 1.5 | $51M | -15% | 550k | 92.37 |
|
Xenon Pharmaceuticals (XENE) | 1.5 | $50M | 1.3M | 38.99 |
|
|
West Pharmaceutical Services (WST) | 1.4 | $48M | +6% | 146k | 329.39 |
|
Penumbra (PEN) | 1.4 | $48M | -47% | 265k | 179.97 |
|
EXACT Sciences Corporation (EXAS) | 1.4 | $46M | +2% | 1.1M | 42.25 |
|
Agios Pharmaceuticals (AGIO) | 1.4 | $45M | -40% | 1.0M | 43.12 |
|
Sarepta Therapeutics (SRPT) | 1.4 | $45M | -13% | 284k | 158.00 |
|
Irhythm Technologies (IRTC) | 1.3 | $43M | 398k | 107.64 |
|
|
Structure Therapeutics Sponsored Ads Call Option (GPCR) | 1.3 | $42M | +158% | 1.1M | 39.27 |
|
Ascendis Pharma A/s Sponsored Adr (ASND) | 1.2 | $40M | 290k | 136.38 |
|
|
Insulet Corporation (PODD) | 1.2 | $39M | -39% | 195k | 201.80 |
|
Travere Therapeutics (TVTX) | 1.1 | $37M | +30% | 4.5M | 8.22 |
|
Brooks Automation (AZTA) | 1.1 | $37M | 696k | 52.62 |
|
|
Revolution Medicines (RVMD) | 1.1 | $37M | +2% | 943k | 38.81 |
|
Kymera Therapeutics (KYMR) | 1.0 | $35M | -23% | 1.2M | 29.85 |
|
Mereo Biopharma Group Spon Ads (MREO) | 1.0 | $33M | +14% | 9.3M | 3.60 |
|
Warby Parker Cl A Com (WRBY) | 1.0 | $33M | 2.1M | 16.06 |
|
|
Immunovant (IMVT) | 0.9 | $31M | +3% | 1.2M | 26.40 |
|
Align Technology (ALGN) | 0.9 | $31M | -42% | 128k | 241.43 |
|
Akero Therapeutics (AKRO) | 0.8 | $25M | -17% | 1.1M | 23.46 |
|
Johnson & Johnson (JNJ) | 0.7 | $25M | NEW | 170k | 146.16 |
|
Lifestance Health Group (LFST) | 0.7 | $24M | 4.8M | 4.91 |
|
|
Zai Lab Adr (ZLAB) | 0.7 | $23M | 1.3M | 17.33 |
|
|
Pacira Pharmaceuticals (PCRX) | 0.7 | $23M | -25% | 785k | 28.61 |
|
Legend Biotech Corp Sponsored Ads (LEGN) | 0.7 | $22M | 506k | 44.29 |
|
|
BioCryst Pharmaceuticals (BCRX) | 0.7 | $22M | +3% | 3.6M | 6.18 |
|
Novo-nordisk A S Adr (NVO) | 0.6 | $21M | 148k | 142.74 |
|
|
Oscar Health Cl A (OSCR) | 0.6 | $20M | -40% | 1.3M | 15.82 |
|
Nuvalent Inc-a (NUVL) | 0.6 | $19M | +104% | 256k | 75.86 |
|
Krystal Biotech (KRYS) | 0.6 | $19M | 106k | 183.64 |
|
|
Inspire Med Sys (INSP) | 0.5 | $17M | 130k | 133.83 |
|
|
Inozyme Pharma (INZY) | 0.5 | $17M | 3.7M | 4.46 |
|
|
Dyne Therapeutics (DYN) | 0.5 | $16M | +2% | 461k | 35.29 |
|
Dynavax Technologies Corp Com New (DVAX) | 0.4 | $15M | -22% | 1.3M | 11.23 |
|
Pharvaris N V (PHVS) | 0.4 | $14M | 757k | 18.80 |
|
|
Immunocore Hldgs Ads (IMCR) | 0.4 | $14M | -82% | 419k | 33.89 |
|
Vera Therapeutics Cl A (VERA) | 0.4 | $14M | +11% | 381k | 36.18 |
|
Crinetics Pharmaceuticals In (CRNX) | 0.4 | $13M | 289k | 44.79 |
|
|
Prothena Corp SHS (PRTA) | 0.4 | $13M | 625k | 20.64 |
|
|
Olink Hldg Ab Sponsored Ads (OLK) | 0.4 | $13M | -70% | 500k | 25.48 |
|
Charles River Laboratories (CRL) | 0.4 | $12M | +24% | 60k | 206.58 |
|
BioMarin Pharmaceutical (BMRN) | 0.4 | $12M | 151k | 82.33 |
|
|
Amicus Therapeutics (FOLD) | 0.4 | $12M | +5% | 1.2M | 9.92 |
|
Nevro (NVRO) | 0.4 | $12M | +29% | 1.4M | 8.42 |
|
Cullinan Oncology (CGEM) | 0.3 | $12M | NEW | 658k | 17.44 |
|
Enliven Therapeutics (ELVN) | 0.3 | $10M | 429k | 23.37 |
|
|
Jasper Therapeutics Com New (JSPR) | 0.3 | $9.2M | 404k | 22.70 |
|
|
Novavax Com New (NVAX) | 0.3 | $8.5M | +25% | 675k | 12.66 |
|
Accolade (ACCD) | 0.2 | $8.2M | -35% | 2.3M | 3.58 |
|
Edap Tms S A Sponsored Adr (EDAP) | 0.2 | $8.0M | 1.5M | 5.44 |
|
|
Springworks Therapeutics (SWTX) | 0.2 | $7.5M | NEW | 200k | 37.67 |
|
Neumora Therapeutics (NMRA) | 0.2 | $7.5M | +17% | 760k | 9.83 |
|
Applied Therapeutics (APLT) | 0.2 | $7.3M | +3% | 1.6M | 4.67 |
|
Aurinia Pharmaceuticals (AUPH) | 0.2 | $6.7M | +2% | 1.2M | 5.71 |
|
Mersana Therapeutics (MRSN) | 0.2 | $6.1M | 3.0M | 2.01 |
|
|
Beam Therapeutics (BEAM) | 0.2 | $5.9M | +69% | 250k | 23.43 |
|
Acumen Pharmaceuticals (ABOS) | 0.2 | $5.6M | 2.3M | 2.42 |
|
|
Compass Therapeutics (CMPX) | 0.2 | $5.5M | 5.5M | 1.00 |
|
|
Apellis Pharmaceuticals (APLS) | 0.2 | $5.4M | NEW | 141k | 38.36 |
|
Gossamer Bio Note 5.000% 6/0 (Principal) | 0.1 | $4.7M | 9.6M | 0.49 |
|
|
Fulcrum Therapeutics (FULC) | 0.1 | $4.5M | 728k | 6.20 |
|
|
Macrogenics (MGNX) | 0.1 | $4.5M | -19% | 1.1M | 4.25 |
|
Mineralys Therapeutics (MLYS) | 0.1 | $4.4M | -52% | 379k | 11.70 |
|
Biohaven (BHVN) | 0.1 | $4.4M | 128k | 34.71 |
|
|
Pliant Therapeutics (PLRX) | 0.1 | $4.1M | 385k | 10.75 |
|
|
Pulmonx Corp (LUNG) | 0.1 | $4.1M | 652k | 6.34 |
|
|
Perspective Therapeutics Com New (CATX) | 0.1 | $4.0M | NEW | 401k | 9.97 |
|
Autolus Therapeutics Spon Ads (AUTL) | 0.1 | $3.6M | 1.0M | 3.48 |
|
|
Essa Pharma Com New (EPIX) | 0.1 | $3.6M | 677k | 5.26 |
|
|
Aclaris Therapeutics (ACRS) | 0.1 | $3.0M | 2.8M | 1.10 |
|
|
Gossamer Bio (GOSS) | 0.1 | $2.9M | 3.3M | 0.90 |
|
|
Travere Therapeutics Note 2.500% 9/1 (Principal) | 0.1 | $2.9M | 3.3M | 0.89 |
|
|
Xilio Therapeutics (XLO) | 0.1 | $2.8M | +108% | 3.0M | 0.95 |
|
Sagimet Biosciences Com Ser A (SGMT) | 0.1 | $2.7M | +2% | 788k | 3.42 |
|
Leap Therapeutics Com New (LPTX) | 0.1 | $2.5M | +38% | 1.3M | 1.96 |
|
Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.1 | $2.4M | 2.4M | 0.97 |
|
|
Vigil Neuroscience (VIGL) | 0.1 | $1.9M | 472k | 4.00 |
|
|
Compugen Ord (CGEN) | 0.1 | $1.7M | -23% | 990k | 1.68 |
|
Spruce Biosciences (SPRB) | 0.0 | $1.4M | 2.6M | 0.52 |
|
|
Kyverna Therapeutics (KYTX) | 0.0 | $1.3M | 179k | 7.50 |
|
|
Korro Bio (KRRO) | 0.0 | $1.2M | NEW | 36k | 33.87 |
|
Allakos (ALLK) | 0.0 | $1.2M | NEW | 1.2M | 1.00 |
|
Biomea Fusion (BMEA) | 0.0 | $815k | 181k | 4.50 |
|
|
Vincerx Pharma Com New (VINC) | 0.0 | $722k | 892k | 0.81 |
|
|
Nevro Corp Note 2.750% 4/0 (Principal) | 0.0 | $483k | 500k | 0.97 |
|
|
Talphera Com New (TLPH) | 0.0 | $282k | 317k | 0.89 |
|
|
Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $21k | 134k | 0.16 |
|
Past Filings by Rock Springs Capital Management
SEC 13F filings are viewable for Rock Springs Capital Management going back to 2013
- Rock Springs Capital Management 2024 Q2 filed Aug. 14, 2024
- Rock Springs Capital Management 2024 Q1 filed May 15, 2024
- Rock Springs Capital Management 2023 Q3 filed Nov. 14, 2023
- Rock Springs Capital Management 2023 Q2 filed Aug. 14, 2023
- Rock Springs Capital Management 2023 Q1 filed May 15, 2023
- Rock Springs Capital Management 2022 Q4 filed Feb. 14, 2023
- Rock Springs Capital Management 2022 Q3 filed Nov. 14, 2022
- Rock Springs Capital Management 2022 Q2 filed Aug. 15, 2022
- Rock Springs Capital Management 2022 Q1 filed May 16, 2022
- Rock Springs Capital Management 2021 Q4 filed Feb. 14, 2022
- Rock Springs Capital Management 2021 Q3 filed Nov. 15, 2021
- Rock Springs Capital Management 2021 Q2 filed Aug. 16, 2021
- Rock Springs Capital Management 2021 Q1 filed May 17, 2021
- Rock Springs Capital Management 2020 Q4 filed Feb. 16, 2021
- Rock Springs Capital Management 2020 Q3 filed Nov. 16, 2020
- Rock Springs Capital Management 2020 Q2 filed Aug. 14, 2020